Strategic alliances – what’s the big deal?
With in-house R&D productivity failing and healthcare cost-containment policy driving the need for differentiation in new product flow, establishing effective alliance networks to secure innovation is critical for pharma. 

Alliances will continue to play a central role in the evolution of the global pharmaceutical industry and Datamonitor has just the report to help you overcome the mechanisms underpinning successful early and late stage licensing deals: 

Optimizing Licensing Strategies for the 21st Century: Creating Win-Win Pharmaceutical and Biotech Licensing Deals 

Use this report to understand the drivers behind your potential partner's licensing decisions and how to maximize a win-win deal development. 

• This report provides recommendation-driven insight into the role of successful vertical alliance portfolio management in responding to and driving corporate strategy.
• It analyzes drivers and resistors for early and late stage in- and out-licensing, as well as strategic goals for win-win licensing deals.
• It includes case studies of the key steps in effective deal negotiation and structuring for both early and late stage deals.

To order click the title: Optimizing Licensing Strategies for the 21st Century: Creating Win-Win Pharmaceutical and Biotech Licensing Deals 


To order these reports contact peter.barfoot@bioportfolio.com or telephone +44 1300 321501 or +1 415 680 2472 and a representative will get back to you.

You can also order on line at: http://www.bioportfolio.com/cgi-bin/acatalog/search.html